You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Organized Lipid Matrix: Fatty Acids and Choline in CF
SBC: AVANTI POLAR LIPIDS, INC. Topic: N/AIndividuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased levels of linoleic acid and an increased triene/tetraene ...
SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health -
Development and validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 103Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Cartilage Regeneration with Tunable Inflammation Resistance
SBC: Cytex Therapeutics, Inc. Topic: RAbstract: Femoroacetabular impingement or FAI is a commonly diagnosed condition affecting a younger patient population than the general osteoarthritis (OA) population. Untreated, FAI invariably leads to OA and, ultimately, total hip arthroplasty (THA). The fact that most FAI diagnoses are made in patients under the age of 40, with many in their late teens and twenties, makes FAI all the more clini ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Knowledge Management System for Multilingual Health Content
SBC: Transcendent International, LLC Topic: N/ADESCRIPTION (provided by applicant): The aim of the proposed project is to develop an advanced, web-based knowledge management system for the creation and distribution of multilingual, patient-oriented documents. The system provides a vast library of pre-translated documents and document templates for medical, educational, and administrative materials used in patient-care. System users will be abl ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB
SBC: CELLF-BIO LLC Topic: 300Project Summary/Abstract:Fecal incontinence (FI), the involuntary soiling of various amounts of liquid and solid stool, is often devastating from a social, psychological, and hygiene perspective. Men and women suffer from FI equally with a range of 2 - 6% in people aged 20 - 30 years. The prevalence increases to over 15% in people older than 70 years1. FI may result from an isolated or combined lo ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
SBC: Focal Medical, Inc. Topic: 102PROJECT SUMMARY Under the parent grant award 2R44CA224460, Advanced Chemotherapy Technologies (ACT) developed an Implantable Iontophoresis Chemotherapy Delivery Device (ACT-IOP-003) that facilitates the infusion of a wide variety of chemotherapy agents directly into the cancer they are intended to treat, thereby minimizing systemic toxic exposure. ACT continues to focus specifically on treating pa ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
A rationally-designed, live-attenuated RSV vaccine for the elderly
SBC: Codagenix Inc. Topic: NIAIDPROJECT SUMMARY/ABSTRACT Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover within two weeks, but RSV is the most common cause of bronchiolitis and pneumonia in children under one year of age, and leads to hospitalization of ~177,000 adults aged 65 and older of which ~14,000 die annually. Despite many attempts, a vaccin ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Human PSMA MAb Radioimmunotherapy for Prostate Cancer
SBC: PROGENICS PHARMACEUTICALS, INC. Topic: N/AProstate cancer is the most common cancer of men in the United States with approximately 189,000 new cases and 30,000 deaths in 2002. Recurrent disease can be controlled temporarily with androgen ablation. However, almost all prostate carcinomas eventuall
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Development of PSMA-based recombinant protein vaccines
SBC: PROGENICS PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Prostate cancer is the most common cancer of men in the United States with approximately 189,000 new cases and 30,000 deaths in 2002. Recurrent disease can be controlled temporarily with androgen ablation. However, alm
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD
SBC: OLIGOMERIX INC Topic: RPROJECT SUMMARY: This R44 supplement application is focused on the development of a comprehensive publication strategy to meet the company’s long-standing goal of disseminating its findings to the scientific community. The proposed work is designed to create a long term publication plan for the company which will include the writing and publishing of (2) manuscripts during the project term. The ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health